Clearstead Advisors, LLC Lineage Cell Therapeutics, Inc. Transaction History
Clearstead Advisors, LLC
- $6.94 Billion
- Q2 2025
A detailed history of Clearstead Advisors, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 1,253 shares of LCTX stock, worth $2,130. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,253Holding current value
$2,130% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
142Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$84.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$16.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$14.4 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$11.5 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.17 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $289M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...